Former President · Aligos Therapeutics, Inc. (ALGS)

Leonid Beigelman

A named executive officer of Aligos Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$955,127

Salary $444,265Stock awards $0

FY2022: $1,378,244

2nd of 4 named executive officers at Aligos Therapeutics by FY2023 total.

4 named officers on file for Aligos Therapeutics, FY2023

Leonid Beigelman’s pay file — $29

  • 5 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aligos Therapeutics’s whole pay program stands against its peers

  • Aligos Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALGS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2024 (DEF 14A).

Free

Get Leonid Beigelman’s full pay file as a PDF — free

More than this page: up to 10 years of Leonid’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Leonid Beigelman compensation by year

Aligos Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as Aligos Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023
Salary$400,000$415,033$464,094$464,094$444,265
Bonus$0$0$0$0$0
Stock awards$0$0$0$0$0
Option awards$0$3,729,360$0$713,811$156,674
Non-equity incentive$152,000$252,225$195,685$167,074$0
Pension and deferred compensation$0$0$0$0$0
All other$2,957$23,574$42,474$33,265$354,188
Total$554,957$4,420,192$702,253$1,378,244$955,127

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aligos Therapeutics, Inc. DEF 14A filed April 29, 2024, accession 0001193125-24-122181, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aligos Therapeutics, Inc. filed document, accession 0001193125-24-122181. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.

$555K
$4.4M
$702K
$1.4M
$955K
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveOption awardsAll other

Aligos Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Lawrence BlattPresident and Chief Executive Officer$1,344,458
Leonid Beigelman · this pageFormer President$955,127
Matthew McClureExecutive Vice President, Chief Medical Officer$837,724
Julian SymonsExecutive Vice President, Chief Scientific Officer$836,319

The full Aligos Therapeutics compensation record

free company brief

This page is one person within Aligos Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aligos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Leonid Beigelman's compensation dossier · One-time report. No refunds.